3014 Background: Dendrimer nanoparticles enable prolonged cytotoxic drug targeting to
tumors. DEP SN38 is a water-soluble version of SN38, the active metabolite of irinotecan …

Background: Dendrimers are highly branched nanoparticles that achieve significant tumor
targeting of cytotoxic drugs. DEP SN38 (or DEP irinotecan) is a highly optimised dendrimer …

Irinotecan (Camptosar®) is a water-soluble prodrug of the potent topoisomerase I inhibitor
SN-38 used clinically to treat multiple cancers. Irinotecan must be metabolized to its active …

Background: Irinotecan is a topoisomerase 1 inhibitor pro-drug used to treat gastrointestinal
(GI) cancers including as first line for colorectal cancer (CRC) as part of the FOLFIRI plus …

2557 Background: DTS-108 is a soluble pro-drug of SN38, the active metabolite of
irinotecan, where the SN38 moiety is covalently linked to a 20AA peptide through a specific …

3580 Background: TAS-102 (FTD/TPI) is a combination of a nucleoside analogue and a
thymidine phosphorylase inhibitor, and has showed activity in 5FU-resistant CRC. Nal-IRI …

2547 Background: Irinotecan (CPT-11) is a prodrug of SN-38 that has antitumor activity in a
wide range of solid tumors. IHL-305 is a PEGylated-liposomal formulation of irinotecan …

Purpose: This study was designed to establish the maximum tolerated dose (MTD) and to
evaluate tolerability, pharmacokinetics, and antitumor activity of etirinotecan pegol …

Background PEP02 (also known as MM-398, nal-IRI) is a novel nanoparticle formulation of
irinotecan encapsulated in liposomes. The aims of this study were to investigate the dose …

Background Trifluridine/tipiracil (FTD/TPI, TAS-102) is a combination of a nucleoside
analogue and a thymidine phosphorylase inhibitor, with treatment activity in 5FU-resistant …